214 related articles for article (PubMed ID: 24815061)
1. Three-year cost-effectiveness model for non-animal stabilized hyaluronic acid and dextranomer copolymer compared with sacral nerve stimulation after conservative therapy for the management of fecal incontinence.
Bernstein MA; Purdy CH; Becker A; Magar R
Clin Ther; 2014 Jun; 36(6):890-905.e3. PubMed ID: 24815061
[TBL] [Abstract][Full Text] [Related]
2. A systematic review and network meta-analysis comparing treatments for faecal incontinence.
Simillis C; Lal N; Pellino G; Baird D; Nikolaou S; Kontovounisios C; Smith JJ; Tekkis PP
Int J Surg; 2019 Jun; 66():37-47. PubMed ID: 31022519
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of sacral neuromodulation (SNM) with Interstim for fecal incontinence patients in Spain.
Brosa M; Muñoz-Duyos A; Navarro-Luna A; Rodriguez JM; Serrano D; Gisbert R; Dziekan K; Segú JL
Curr Med Res Opin; 2008 Mar; 24(3):907-18. PubMed ID: 18279582
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy of dextranomer in stabilized hyaluronic acid (NASHA/Dx) for treatment of faecal incontinence.
La Torre F; de la Portilla F
Colorectal Dis; 2013 May; 15(5):569-74. PubMed ID: 23374680
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of NASHA Dx injection therapy for treatment of fecal incontinence.
Mellgren A; Matzel KE; Pollack J; Hull T; Bernstein M; Graf W;
Neurogastroenterol Motil; 2014 Aug; 26(8):1087-94. PubMed ID: 24837493
[TBL] [Abstract][Full Text] [Related]
6. Identifying factors associated with clinical success in patients treated with NASHA(®)/Dx injection for fecal incontinence.
Franklin H; Barrett AC; Wolf R
Clin Exp Gastroenterol; 2016; 9():41-7. PubMed ID: 27042136
[TBL] [Abstract][Full Text] [Related]
7. Treatment of stress urinary incontinence with non-animal stabilised hyaluronic acid/dextranomer (NASHA/Dx) gel : An analysis of utility and cost.
Kobelt G; Fianu-Jonasson A
Clin Drug Investig; 2006; 26(10):583-91. PubMed ID: 17163292
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, sham-controlled trial.
Graf W; Mellgren A; Matzel KE; Hull T; Johansson C; Bernstein M;
Lancet; 2011 Mar; 377(9770):997-1003. PubMed ID: 21420555
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of sacral nerve stimulation for faecal incontinence.
Dudding TC; Meng Lee E; Faiz O; Parés D; Vaizey CJ; McGuire A; Kamm MA
Br J Surg; 2008 Sep; 95(9):1155-63. PubMed ID: 18581439
[TBL] [Abstract][Full Text] [Related]
10. Injectable bulking treatment of persistent fecal incontinence in adult patients after anorectal malformations.
Danielson J; Karlbom U; Wester T; Graf W
J Pediatr Surg; 2020 Mar; 55(3):397-402. PubMed ID: 31493885
[TBL] [Abstract][Full Text] [Related]
11. Validity of the ≥50% Response Threshold in Treatment With NASHA/Dx Injection Therapy for Fecal Incontinence.
Sanchez JE; Brenner DM; Franklin H; Yu J; Barrett AC; Paterson C
Clin Transl Gastroenterol; 2015 Jan; 6(1):e70. PubMed ID: 25588523
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of a novel system (NASHA/Dx copolymer using the Implacer device) for treatment of stress urinary incontinence.
van Kerrebroeck P; ter Meulen F; Larsson G; Farrelly E; Edwall L; Fianu-Jonasson A
Urology; 2004 Aug; 64(2):276-81. PubMed ID: 15302478
[TBL] [Abstract][Full Text] [Related]
13. A short- and long-term follow-up study of intersphincteric NASHA Dx implants for fecal incontinence.
Ezra E; Danielsson JM; Graf W
Tech Coloproctol; 2022 Oct; 26(10):813-820. PubMed ID: 35752984
[TBL] [Abstract][Full Text] [Related]
14. Clinical and cost effectiveness of sacral nerve stimulation for faecal incontinence.
Muñoz-Duyos A; Navarro-Luna A; Brosa M; Pando JA; Sitges-Serra A; Marco-Molina C
Br J Surg; 2008 Aug; 95(8):1037-43. PubMed ID: 18574847
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and quality of life 2 years after treatment for faecal incontinence with injectable bulking agents.
Danielson J; Karlbom U; Wester T; Graf W
Tech Coloproctol; 2013 Aug; 17(4):389-95. PubMed ID: 23224913
[TBL] [Abstract][Full Text] [Related]
16. Non-Animal Stabilized Hyaluronic Acid/Dextranomer Gel (NASHA/Dx, Deflux) for Endoscopic Treatment of Vesicoureteral Reflux: What Have We Learned Over the Last 20 Years?
Kirsch AJ; Cooper CS; Läckgren G
Urology; 2021 Nov; 157():15-28. PubMed ID: 34411597
[TBL] [Abstract][Full Text] [Related]
17. Sacral neuromodulation for the treatment of fecal incontinence: analysis of cost-effectiveness.
Indinnimeo M; Ratto C; Moschella CM; Fiore A; Brosa M; Giardina S
Dis Colon Rectum; 2010 Dec; 53(12):1661-9. PubMed ID: 21178862
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance imaging to evaluate NASHA/Dx gel (Zuidex) for stress urinary incontinence.
Fianu-Jonasson A; Edwall L; Wiberg MK
Int J Clin Pract; 2006 Oct; 60(10):1181-6. PubMed ID: 16981962
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence.
Siddiqui NY; Amundsen CL; Visco AG; Myers ER; Wu JM
J Urol; 2009 Dec; 182(6):2799-804. PubMed ID: 19837427
[TBL] [Abstract][Full Text] [Related]
20. Quality of life is markedly improved in patients with fecal incontinence after sacral nerve stimulation.
Devroede G; Giese C; Wexner SD; Mellgren A; Coller JA; Madoff RD; Hull T; Stromberg K; Iyer S;
Female Pelvic Med Reconstr Surg; 2012; 18(2):103-12. PubMed ID: 22453321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
